Rhythm Pharmaceuticals

Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.

 
 
  • ABOUT RHYTHM
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORY BOARD
  • PIPELINE
    • SETMELANOTIDE: A FIRST-IN-CLASS MC4 AGONIST
    • RARE GENETIC DISORDERS OF OBESITY
    • PUBLISHED RESEARCH
  • INVESTORS & MEDIA
    • INVESTOR OVERVIEW
    • STOCK INFORMATION
    • SEC FILINGS
    • NEWS & RESOURCES
    • EVENT CALENDAR
    • CORPORATE GOVERNANCE
    • SHAREHOLDER SERVICES
  • CAREERS
  • CONTACT
    • CONTACT RHYTHM
    • DIRECTIONS
INVESTORS & MEDIA > IR CONTACT

IR CONTACT

Hannah Deresiewicz
Phone: 212-362-1200
E-mail: hannahd@sternir.com

  • INVESTORS & MEDIA
    • INVESTOR OVERVIEW
    • STOCK INFORMATION
    • SEC FILINGS
    • NEWS & RESOURCES
    • EVENTS & PRESENTATIONS
    • CORPORATE GOVERNANCE
    • ANNUAL REPORT AND PROXY
    • SHAREHOLDER SERVICES
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contact
Financial Tear Sheet

SITEMAP  /  TERMS OF USE  /  PRIVACY POLICY  /  Site Design  /  © 2018 RHYTHM PHARMACEUTICALS, INC. All Rights Reserved. MC4R-C0076